Lubomir Sokol – författare

Burkitt lymphoma (BL) is a lymphoid neoplasm originating from a mature, follicular center B-cell that is phenotypically positive for CD10, BCL-6, LOM2, and HGAL, with a hallmark genetic translocation involving the MYC gene (at 8q24) and its partner - either immunoglobulin heavy chain (14q) or light chain (kappa at 2q and lambda at 22q) - and a very aggressive clinical nature. BL can be divided into three clinical subcategories: Endemic, sporadic and HIV/AIDS/immunodeficiency with prevalence in children, adolescents and young adults. Clinical manifestations could slightly be variable upon its clinical subcategories; however, they share certain similar features, e.g., fast growing mass, frequent extranodal presentation, are associated with EBV infection, and sensitive to tumor reduction therapy with a high risk of tumor lysis syndrome and uric acid nephropathy. It is important to differentiate BL from other aggressive types of B-cell lymphomas as with intensive, short-term chemotherapy, e.g., hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, and cytarabine). Additionally, CNS prophylaxis BL showed a much better clinical response. Nearly all types of BL lack or dimly express BCL-2, differentiating it from other mimickers. A diagnostic challenging variant of BL - an MYC-negative harboring 11q abnormalities, namely "e;Burkitt-like lymphoma with an 11q aberration"e; - has been recently proposed. Novel next generation sequencing and gene expression profiling has brought about new insights into BL. TCF3(E2A), a transcription factor involving the regulation of lymphoid cell survival and proliferation, its negative regulator known as ID3, and the downstream gene CCND3 were also frequently mutated in cases of BL. The characterization of molecular biology and the genetic profile of BL leads to the future of personalized medicine and targeted therapy. This book focuses on the epidemiology, etiology, clinical presentations/staging, differential diagnoses, MYC-driven pathogenesis and therapeutic options concerning BL. These updates in BL and associated EBV- or MYC-positive diseases will benefit trainees, physicians and basic scientists who engage in the diagnosis, treatment, and novel drug development for this disease.

In the current digital era with the exponential growth of medical knowledge, voluminous textbooks have gradually been replaced by the pocketbooks with tables, figures, images, and e-links to digital book versions with supplemental materials available online. The advent of novel next-generation sequencing (NGS) and multi-omics single cell methods have uncovered causative molecular mechanisms in most of the known non-neoplastic hematologic disorders.  There is an urgent need for a concise and up-to-date handbook focused on non-malignant hematology.The book describes characteristic clinical features and state-of-the-art diagnostic approaches of non-neoplastic hematologic disorders. It introduces modern molecular biomarkers with enormous diagnostic and prognostic value and novel targeted gene therapy. Differential diagnosis also includes relevant hematologic malignancies that could represent diagnostic pitfalls. Chapters include take home points for each disorder in concise and easy memorable manner. The book also provides diagnostic algorithms, novel prognostic and predictive factors, up-to-date treatment options, clinically relevant molecular signatures, and ongoing promising clinical trials if available. There are more than 100 questions and answers with comments on laboratory values, updated cytogenetic and mutational profiles.Non-Neoplastic Hematologic Disorders: A Quick Review of Modern Diagnostic and Therapeutic Approaches provides concise clinical and laboratory information about most common non-neoplastic hematologic disorder for practicing hematologists, oncologists, hematopathologists, molecular pathologists, internal medicine specialists, pediatricians, research nurses, nurse practitioners, and trainees at all levels.